Search the Newsreel

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate Early Q1 2027 Phase 1 …

Protagonist Therapeutics (NASDAQ: PTGX) turns Q2 2026 loss into profit

Protagonist Therapeutics (NASDAQ: PTGX) reported a significant financial turnaround in Q2 2026, shifting from a loss to a net income of $162.8 million and diluted earnings per share of $2.29. This was primarily driven by approximately $213.5 million in license and collaboration revenue, including …

Protagonist Therapeutics (PTGX) Earnings Date and Reports 2026

Protagonist Therapeutics (NASDAQ:PTGX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Protagonist Therapeutics (PTGX) reported Q2 earnings of $2.29 per share, significantly beating the Zacks Consensus Estimate of $2.11 and reversing a loss from the prior year. Despite missing revenue estimates for the quarter, the company's shares have risen 55.5% year-to-date. The stock currently holds …

PTGX|Protagonist Therapeutics Inc|Price:132.170|Chg%:-4.470

This article provides an in-depth analysis of Protagonist Therapeutics Inc. (PTGX), covering its market trends, real-time quotes, and related analysis. It highlights the company's strong fundamentals and growth potential, despite a recent turnaround to loss, and offers a comprehensive look at its financial indicators, …

Two New Hires Get Protagonist Stock Awards Vested Over Four Years

Protagonist Therapeutics granted inducement equity awards to two new employees on July 31, 2026, comprising options to purchase 7,300 shares and 1,975 Restricted Stock Units (RSUs). These awards, with an exercise price matching the July 31 Nasdaq closing price of $136.64, are designed to …

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics (Nasdaq:PTGX) announced that on July 31, 2026, it granted inducement awards to two new employees. These awards, consisting of options to purchase 7,300 shares and 1,975 Restricted Stock Units (RSUs), were made under the company's Amended and Restated Inducement Plan. The grants …

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech Pioneer with Robust Revenue Growth and Promising Pipeline

(PTGX) Movement as an Input in Quant Signal Sets

This article analyzes Protagonist Therapeutics Inc. (NASDAQ: PTGX) using AI models to provide quantitative trading signals. It indicates neutral near and mid-term readings but a positive long-term bias for the stock. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined with specific …

Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Protagonist Therapeutics Inc (PTGX), noting its current valuation score of 4.19, which ranks it low within the Biotechnology & Medical Research industry. The company's P/E ratio is reported at -75.74, showing significant fluctuations from its recent high …

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Stempoint Capital LP

Stempoint Capital LP has increased its holdings in Protagonist Therapeutics (NASDAQ:PTGX) by 22.1%, acquiring an additional 13,147 shares to own a total of 72,577 shares valued at $7.65 million. This makes Protagonist Therapeutics the 26th largest holding for Stempoint Capital, comprising about 1.5% of …

Protagonist Therapeutics (PTGX) Projected to Post Earnings on Wednesday

Protagonist Therapeutics Inc (PTGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Protagonist Therapeutics Inc (PTGX), focusing on its price momentum, support and resistance levels, and key indicators like MACD, RSI, and moving averages. As of July 28, 2026, PTGX had a price momentum score of 4.02 and was …

Rubric Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX

Rubric Capital Management LP has acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), purchasing 427,998 shares valued at approximately $45.1 million, which represents 0.67% of the company. Institutional investors now own 98.63% of PTGX, despite recent insider selling by the CEO and a …

Protagonist Therapeutics, Inc. $PTGX Stock Position Lifted by Eagle Health Investments LP

Protagonist Therapeutics Inc

This article from TradingKey provides a company overview for Protagonist Therapeutics Inc (PTGX), focusing on its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article primarily displays …

Protagonist Therapeutics Market Sentiment

This article analyzes the market sentiment for Protagonist Therapeutics (PTGX) based on analyst consensus, short interest, options flow, and insider activity. The analyst consensus is "Buy" with 18 analysts, and the average price target is $104. Short interest is 13.9% and declining, which is …

Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Protagonist Therapeutics Inc (PTGX) has an earnings forecast score of 8.57, ranking 98th in the Biotechnology & Medical Research industry. Analysts have an average price target of $91.00 for PTGX, with most analysts recommending a "Buy" rating. The company's expected revenue for the next …

Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Protagonist Therapeutics Inc (PTGX) regarding its dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock performance data, including its market cap.

Protagonist Therapeutics, Inc. Revenue Breakdown – NASDAQ:PTGX

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) generated $46.02 million in revenue last year, primarily from its Peptide Therapeutics segment, a significant decrease from the previous year's $434.43 million. The United States was the company's largest contributor to revenue.

Protagonist Therapeutics, Inc. $PTGX Shares Sold by Atika Capital Management LLC

Atika Capital Management LLC reduced its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 27.8% in Q1 2026, selling 23,900 shares, though institutional ownership remains high at 98.63%. Despite Atika's sale, other major institutional investors like Vanguard, State Street, and Wellington increased their positions. Analysts maintain …

Protagonist Therapeutics (PTGX) Stock Looks Stretched As A Price Target Boost Lands

Protagonist Therapeutics (PTGX) has seen a significant 7x return over the last three years, leading to a stretched valuation despite a recent price target boost from Barclays. The stock appears overvalued on market multiples and shows a mixed picture on broader valuation checks, raising …

PROTAGONIST THERAPEUTICS INC : JEFFERIES RAISES TARGET PRICE TO $172 FROM $121

Jefferies has raised its target price for Protagonist Therapeutics Inc. to $172 from $121, according to a report from Reuters. The article states that this content reflects only the author's opinion and should not be used as investment advice.

Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com

Protagonist Therapeutics (PTGX) stock reached an all-time high of $141.79, currently trading at $143.26 with a market capitalization of $9.06 billion. The company has seen significant growth, with a 155.18% increase over the past year and a 61% year-to-date return, driven by positive market …

Protagonist Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

This document is a Rule 144 notice of proposed sale of securities for Protagonist Therapeutics. Rule 144 allows public resale of restricted and control securities if certain conditions are met.

Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open

Protagonist Therapeutics (PTGX) saw a 5.7% increase, participating in a broad biotech rally despite mixed signals on its valuation. While the company appears overvalued based on its Price-to-Book multiple of 13.8x compared to the industry average, a Discounted Cash Flow (DCF) model suggests it's …

Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary

Protagonist Therapeutics (PTGX) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting its focus on novel peptide therapeutics and its two lead assets, icotrokinra and rusfertide. Icotrokinra, an oral IL-23 blocker, targets psoriasis, while rusfertide, an injectable hepcidin mimetic, targets polycythemia vera, with …

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Moderate Buy" by Brokerages

Protagonist Therapeutics (NASDAQ:PTGX) has received a "Moderate Buy" consensus rating from brokerages, based on analyst ratings with an average 12-month price target of $123. The company's stock was trading up, nearing its 52-week high, and recently beat earnings expectations. However, there have been recent …

Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally

Protagonist Therapeutics saw its shares surge 5.7% on Friday, closing at $139.60, as the biotech company benefited from a broad sector-wide rally. This synchronized movement among biotechnology stocks suggests that macro factors and a shift in investor risk appetite, rather than company-specific news, were …

Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com

Citizens increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $165 from $137, while maintaining a Market Outperform rating, due to better-than-expected prescription volume for its drug Icotyde. The firm now estimates approximately $8 million in second-quarter royalty revenue for Protagonist Therapeutics and …

Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan

Protagonist Therapeutics (Nasdaq: PTGX) granted equity inducement awards to three new employees on July 15, 2026. These awards include options for 12,600 shares and RSUs for 3,330 shares, with an option exercise price of $135.46. The awards were approved by the compensation committee as …

Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight

Protagonist Therapeutics saw its shares jump 5.3% to $138.27 after Barclays maintained an Overweight rating and significantly raised its price target by 26.9% to $151. This upgrade reflects increasing confidence in the biotechnology company's prospects, driving keen investor interest and a trading volume of …